CITIUS ONCOLOGY, INC. - 8-K Summary
Business Context and Reporting Period
Citius Oncology, Inc. (Nasdaq: CTOR), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on December 23, 2025. The filing serves to announce the company's results of operations for the full fiscal year 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this 8-K. The document solely references the issuance of the full-year 2025 results press release.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 23, 2025) for actual financial figures and operational highlights.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (CTOR) and exchange (Nasdaq Capital Market) for accurate market data retrieval.
- Note that the financial data in the referenced press release is not legally "filed" under Section 18 of the Exchange Act.